BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rett Syndrome readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Rett Syndrome\, from 
 ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07503444-8885@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20290206
DTEND;VALUE=DATE:20290207
SUMMARY:Fintepla (Fenfluramine): Phase 3 readout est. (NCT07503444)
DESCRIPTION:Fintepla (Fenfluramine)\, phase 3\, Rett Syndrome.\nStudy: A Ph
 ase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome\nEstimated prim
 ary completion: 6 February 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/fenfluramine#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07503444
URL:https://assetmemo.bio/drug/fenfluramine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
